74 related articles for article (PubMed ID: 20948186)
1. Investigative clinical study on prostate cancer part III: exploring total PSA and free testosterone distributions and linear correlations in groups and subgroups of operated prostate cancer patients according to the total PSA/FT ratio.
Porcaro AB; Petrozziello A; Romano M; Sava T; Ghimenton C; Caruso B; Migliorini F; Zecchini Antoniolli S; Rubilotta E; Lacola V; Monaco C; Comunale L
Urol Int; 2010; 85(4):406-9. PubMed ID: 20948186
[TBL] [Abstract][Full Text] [Related]
2. Investigative clinical study on prostate cancer part II: on the role of the pretreatment total PSA to free testosterone ratio as a marker assessing prostate cancer prognostic groups after radical retropubic prostatectomy.
Porcaro AB; Monaco C; Romano M; Petrozziello A; Rubilotta E; Lacola V; Sava T; Ghimenton C; Caruso B; Antoniolli SZ; Migliorini F; Comunale L
Urol Int; 2010; 85(2):152-8. PubMed ID: 20616526
[TBL] [Abstract][Full Text] [Related]
3. Investigative clinical study on prostate cancer part VI: Follicle-stimulating hormone and the pituitary-testicular-prostate axis at the time of initial diagnosis and subsequent cluster selection of the patient population.
Porcaro AB; Migliorini F; Petrozziello A; Sava T; Romano M; Caruso B; Cocco C; Ghimenton C; Zecchinini Antoniolli S; Lacola V; Rubilotta E; Monaco C; Comunale L
Urol Int; 2012; 88(2):150-7. PubMed ID: 22205171
[TBL] [Abstract][Full Text] [Related]
4. Investigative clinical study on prostate cancer part IV: exploring functional relationships of total testosterone predicting free testosterone and total prostate-specific antigen in operated prostate cancer patients.
Porcaro AB; Petrozziello A; Migliorini F; Lacola V; Romano M; Sava T; Ghimenton C; Caruso B; Zecchini Antoniolli S; Rubilotta E; Monaco C; Comunale L
Urol Int; 2011; 86(4):399-406. PubMed ID: 21508618
[TBL] [Abstract][Full Text] [Related]
5. Investigative clinical study on prostate cancer part IX and X: estradiol and the pituitary-testicular-prostate axis at the time of initial diagnosis and subsequent cluster selection of the patient population after radical prostatectomy.
Porcaro AB; Ghimenton C; Petrozziello A; Sava T; Migliorini F; Romano M; Caruso B; Cocco C; Antoniolli SZ; Lacola V; Rubilotta E; Monaco C
Anticancer Res; 2012 Oct; 32(10):4523-32. PubMed ID: 23060581
[TBL] [Abstract][Full Text] [Related]
6. Investigative clinical study on prostate cancer part VIII: prolactin hormone and the pituitary-testicular-prostate axis at the time of initial diagnosis and subsequent cluster selection of the patient population after radical prostatectomy.
Porcaro AB; Ghimenton C; Petrozziello A; Migliorini F; Romano M; Sava T; Caruso B; Cocco C; Antoniolli SZ; Lacola V; Rubilotta E; Monaco C; Comunale L
Anticancer Res; 2012 Apr; 32(4):1499-506. PubMed ID: 22493393
[TBL] [Abstract][Full Text] [Related]
7. Free-to-total prostate-specific antigen ratio as a predictor of non-organ-confined prostate cancer (stage pT3).
Aus G; Becker C; Lilja H; Khatami A; Pihl CG; Hugosson J
Scand J Urol Nephrol; 2003; 37(6):466-70. PubMed ID: 14675918
[TBL] [Abstract][Full Text] [Related]
8. The correlation between serum prostate-specific antigen and prostate cancer is not influenced by the serum testosterone concentration.
Monda JM; Myers RP; Bostwick DG; Oesterling JE
Urology; 1995 Jul; 46(1):62-4. PubMed ID: 7541588
[TBL] [Abstract][Full Text] [Related]
9. Prediction of post-radical prostatectomy pathological outcome for stage T1c prostate cancer with percent free prostate specific antigen: a prospective multicenter clinical trial.
Southwick PC; Catalona WJ; Partin AW; Slawin KM; Brawer MK; Flanigan RC; Patel A; Richie JP; Walsh PC; Scardino PT; Lange PH; Gasior GH; Parson RE; Loveland KG
J Urol; 1999 Oct; 162(4):1346-51. PubMed ID: 10492194
[TBL] [Abstract][Full Text] [Related]
10. The preoperative serum ratio of total prostate specific antigen (PSA) to free testosterone (FT), PSA/FT index ratio, and prostate cancer. Results in 220 patients undergoing radical prostatectomy.
Porcaro AB; Caruso B; Terrin A; De Luyk N; Cacciamani G; Corsi P; Inverardi D; De Marchi D; Baldassarre R; Cerruto M; Ghimenton C; Brunelli M; Zecchini Antoniolli S; Petrozziello A; Artibani W
Arch Ital Urol Androl; 2016 Mar; 88(1):17-22. PubMed ID: 27072171
[TBL] [Abstract][Full Text] [Related]
11. Percentage of cancer in prostate biopsies as prognostic factor for staging and postoperative biochemical failure after radical prostatectomy.
Villamón-Fort R; Martínez-Jabaloyas JM; Soriano-Sarriá P; Ramos-Soler D; Pastor-Hernández F; Gil-Salom M
Urol Int; 2007; 78(4):328-33. PubMed ID: 17495491
[TBL] [Abstract][Full Text] [Related]
12. Perineural invasion as a predictor of biochemical outcome following radical prostatectomy for select men with clinically localized prostate cancer.
D'Amico AV; Wu Y; Chen MH; Nash M; Renshaw AA; Richie JP
J Urol; 2001 Jan; 165(1):126-9. PubMed ID: 11125380
[TBL] [Abstract][Full Text] [Related]
13. Investigative clinical study on prostate cancer part VII: prolactin and the pituitary-testis-prostate axis at the time of initial diagnosis and subsequent cluster selection of the patient population.
Porcaro AB; Ghimenton C; Petrozziello A; Migliorini F; Romano M; Sava T; Caruso B; Cocco C; Antoniolli SZ; Lacola V; Rubilotta E; Monaco C; Comunale L
Anticancer Res; 2011 Nov; 31(11):3913-20. PubMed ID: 22110219
[TBL] [Abstract][Full Text] [Related]
14. Accuracy of predicting long-term prostate specific antigen outcome based on early prostate specific antigen recurrence results after radical prostatectomy.
Soergel TM; Koch MO; Foster RS; Bihrle R; Wahle G; Gardner T; Jung SH
J Urol; 2001 Dec; 166(6):2198-201. PubMed ID: 11696735
[TBL] [Abstract][Full Text] [Related]
15. Prediction of pathological stage in patients with clinical stage T1c prostate cancer: the new challenge.
Veltri RW; Miller MC; Mangold LA; O'Dowd GJ; Epstein JI; Partin AW
J Urol; 2002 Jul; 168(1):100-4. PubMed ID: 12050500
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of tissue prostate-specific antigen in endocrine-treated prostate carcinomas.
Stege R; Grande M; Carlström K; Tribukait B; Pousette A
Clin Cancer Res; 2000 Jan; 6(1):160-5. PubMed ID: 10656445
[TBL] [Abstract][Full Text] [Related]
17. Hormonal predictors of prostate cancer.
Sofikerim M; Eskicorapci S; Oruç O; Ozen H
Urol Int; 2007; 79(1):13-8. PubMed ID: 17627161
[TBL] [Abstract][Full Text] [Related]
18. Influence of body mass index and total testosterone level on biochemical recurrence following radical prostatectomy.
Hisasue S; Yanase M; Shindo T; Iwaki H; Fukuta F; Nishida S; Muranaka T; Miyamoto S; Tsukamoto T; Takatsuka K
Jpn J Clin Oncol; 2008 Feb; 38(2):129-33. PubMed ID: 18281308
[TBL] [Abstract][Full Text] [Related]
19. The percentage of prostate needle biopsy cores with carcinoma from the more involved side of the biopsy as a predictor of prostate specific antigen recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.
Freedland SJ; Aronson WJ; Terris MK; Kane CJ; Amling CL; Dorey F; Presti JC
Cancer; 2003 Dec; 98(11):2344-50. PubMed ID: 14635068
[TBL] [Abstract][Full Text] [Related]
20. Percent of prostate needle biopsy cores with cancer is significant independent predictor of prostate specific antigen recurrence following radical prostatectomy: results from SEARCH database.
Freedland SJ; Aronson WJ; Terris MK; Kane CJ; Amling CL; Dorey F; Presti JC;
J Urol; 2003 Jun; 169(6):2136-41. PubMed ID: 12771735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]